Brind.

Scynexis licensed its drug candidate ibrexafungerp to GSK.

2 reports, 2 independent Updated Aug 1

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Scynexis licensed its drug candidate ibrexafungerp to GSK.

Who's involved

What this event is mainly about

GSK Scynexis

Keep exploring

The entities involved

GSK
British multinational pharmaceutical and biotechnology company
- Clement Fourny joins Biodextris as CEO, a company that originated as a GSK development center.Mon 15:26
- GSK acquired Sierra Oncology.Mon 14:28
Scynexis
company in Durham, United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 1manilatimes.net
Aug 25GlobeNewswireSCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025 JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology